Printed from Voxsanity (voxsanity.com.au) — NCT06943872 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have a confirmed diagnosis of CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma), confirmed according to internationally recognised diagnostic standards
People who have already received at least one previous treatment for CLL/SLL, where each treatment course included at least 2 cycles
People who have previously been treated with a type of drug called a BCL2 inhibitor may still be considered, provided their disease stayed in remission for at least 3 years and it has been at least 2 years since their last dose of that drug
People whose general physical functioning is rated at a level of 0, 1, or 2 on a standard medical scale (meaning they are fully active to capable of some self-care, confirm with trial site)
People whose major organs (such as liver and kidneys) are functioning at an adequate level
Who may not be able to join:
People who have a known active related blood cancer called prolymphocytic leukemia, or who are currently suspected of having a transformation of their CLL/SLL into a more aggressive lymphoma (called Richter's transformation)
People who have had a stem cell transplant using their own cells, or a CAR-T cell therapy, within the 3 months before the first dose of the study drug
People who have had a stem cell transplant using donor cells and are currently experiencing graft-versus-host disease, are taking immune-suppressing drugs for that condition, or have taken a specific type of immune-suppressing drug (calcineurin inhibitors) within the 4 weeks before agreeing to join the trial
People whose CLL/SLL has spread to the central nervous system (the brain and spinal cord)
People with severe or seriously debilitating lung or breathing problems
People with significant heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales
St George Hospital, Kogarah, New South Wales
Northern Nsw Health District, Lismore, New South Wales
Macquarie University, North Ryde, New South Wales
Genesiscare North Shore, St Leonards, New South Wales
Sunshine Coast Hospital and Health Service, Birtinya, Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland
Monash Health, Clayton, Victoria
St Vincents Hospital Melbourne, Fitzroy, Victoria
Peter Maccallum Cancer Centre, Melbourne, Victoria
The Alfred Hospital, Melbourne, Victoria
Rockingham Hospital, Cooloongup, Western Australia
Perth Blood Institute, West Perth, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06943872
Sponsor: BeOne Medicines
Phase: Phase 3
Status: Recruiting
Condition: Leukaemia
Trial contact: 1-877-828-5568
More information: https://clinicaltrials.gov/study/NCT06943872
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have a confirmed diagnosis of CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Lymphoma), confirmed according to internationally recognised diagnostic standards
People who have already received at least one previous treatment for CLL/SLL, where each treatment course included at least 2 cycles
People who have previously been treated with a type of drug called a BCL2 inhibitor may still be considered, provided their disease stayed in remission for at least 3 years and it has been at least 2 years since their last dose of that drug
People whose general physical functioning is rated at a level of 0, 1, or 2 on a standard medical scale (meaning they are fully active to capable of some self-care, confirm with trial site)
People whose major organs (such as liver and kidneys) are functioning at an adequate level
Who may not be able to join:
People who have a known active related blood cancer called prolymphocytic leukemia, or who are currently suspected of having a transformation of their CLL/SLL into a more aggressive lymphoma (called Richter's transformation)
People who have had a stem cell transplant using their own cells, or a CAR-T cell therapy, within the 3 months before the first dose of the study drug
People who have had a stem cell transplant using donor cells and are currently experiencing graft-versus-host disease, are taking immune-suppressing drugs for that condition, or have taken a specific type of immune-suppressing drug (calcineurin inhibitors) within the 4 weeks before agreeing to join the trial
People whose CLL/SLL has spread to the central nervous system (the brain and spinal cord)
People with severe or seriously debilitating lung or breathing problems
People with significant heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
BeOne Medicines
Registry
ClinicalTrials.gov
Start date
11 June 2025
Est. completion
30 September 2029
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇮🇪 Ireland
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇬🇧 United Kingdom
🇺🇸 United States
13 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC) for Arm A versus Arm D
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.